Dermata Therapeutics (DRMA) Expected to Announce Quarterly Earnings on Monday

Dermata Therapeutics (NASDAQ:DRMA) is projected to announce its results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter.

Dermata Therapeutics Trading Down 4.0%

Shares of Dermata Therapeutics stock opened at $1.19 on Friday. Dermata Therapeutics has a 1 year low of $1.11 and a 1 year high of $23.70. The company’s fifty day simple moving average is $1.77 and its 200-day simple moving average is $3.10. The company has a market cap of $3.38 million, a price-to-earnings ratio of -0.15 and a beta of 0.60.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Weiss Ratings reissued a “sell (e)” rating on shares of Dermata Therapeutics in a report on Monday, December 29th. Wall Street Zen downgraded shares of Dermata Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Dermata Therapeutics currently has an average rating of “Hold” and an average target price of $10.00.

Institutional Investors Weigh In On Dermata Therapeutics

An institutional investor recently bought a new position in Dermata Therapeutics stock. Clear Street Group Inc. bought a new position in Dermata Therapeutics, Inc. (NASDAQ:DRMA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned about 0.60% of Dermata Therapeutics as of its most recent filing with the Securities and Exchange Commission. 8.67% of the stock is owned by institutional investors and hedge funds.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.